ESMO News

ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific

noreply@esmo.org — Fri, 12 Jun 2026 08:06:00 +00:00

The second edition of the ESMO TAT Asia Congress 2026, taking place from 12 to 14 June in Hong Kong SAR, China, reflects ESMO’s ongoing commitment to working alongside the Asia-Pacific oncology community and fostering global collaboration in developing new anti-cancer therapies.

EMA Recommends Granting a Conditional Marketing Authorisation for Alpelisib

noreply@esmo.org — Fri, 12 Jun 2026 07:06:00 +00:00

It is intended for the treatment of patients with severe or life threatening manifestations of PIK3CA-related overgrowth spectrum

Advanced and Metastatic Prostate Cancer Living Guideline

noreply@esmo.org — Thu, 11 Jun 2026 22:06:00 +00:00

New title prepared by K Fizazi and S Gillessen: The ESMO Advanced and Metastatic Prostate Cancer Living Guideline features all recommendations and algorithms from the 2026 CPG, in a mobile friendly interactive format

Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

noreply@esmo.org — Thu, 11 Jun 2026 07:06:00 +00:00

Findings from the FIGHT-302 study

FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

noreply@esmo.org — Wed, 10 Jun 2026 07:06:00 +00:00

FDA also approved a companion diagnostic device to select patients after cystectomy who have ctDNA molecular residual disease for adjuvant treatment

Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL

noreply@esmo.org — Tue, 09 Jun 2026 07:06:00 +00:00

Findings from the frontMIND study

Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes

noreply@esmo.org — Mon, 08 Jun 2026 12:06:00 +00:00

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

Daraxonrasib Prolongs Survival Among Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

noreply@esmo.org — Mon, 08 Jun 2026 07:06:00 +00:00

Findings from the RASolute 302 study

EMA Recommends Granting a Marketing Authorisation for Camizestrant

noreply@esmo.org — Fri, 05 Jun 2026 07:06:00 +00:00

It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

New ESMO President 2029-2030 Elected

noreply@esmo.org — Wed, 03 Jun 2026 09:06:00 +00:00

ESMO has announced the results of its presidential election, following the closure of voting on Monday, 1 June 2026.

ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF)

noreply@esmo.org — Wed, 03 Jun 2026 09:06:00 +00:00

A robust and well-funded EU Health Programme is essential not only for providing tangible solutions benefitting patients with cancer but also for achieving the goals of Europe’s Beating Cancer Plan & Horizon Europe Mission on Cancer

Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical Prostatectomy for High-Risk Localised or Locally Advanced Prostate Cancer

noreply@esmo.org — Wed, 03 Jun 2026 07:06:00 +00:00

Findings from the PROTEUS study

FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML

noreply@esmo.org — Wed, 03 Jun 2026 07:06:00 +00:00

Evidence for efficacy is based on the results from the Study ASTX727-07

Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC

noreply@esmo.org — Tue, 02 Jun 2026 07:06:00 +00:00

Findings from the LIBRETTO-432 study

ESMO Helps Secure the Adoption of the Precision Medicine Resolution by the Seventy-Ninth World Health Assembly (WHA79)

noreply@esmo.org — Tue, 02 Jun 2026 07:06:00 +00:00

At the WHA79 in Geneva, WHO Member States adopted the resolution ‘Precision medicine: a path towards targeted, personalized and equitable care’, marking an important milestone for global health and giving WHO a mandate to take this agenda forward.

Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma

noreply@esmo.org — Mon, 01 Jun 2026 07:06:00 +00:00

Findings from the HERIZON-GEA-01 study

ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May 2026

noreply@esmo.org — Fri, 29 May 2026 14:05:00 +00:00

The EU is well-placed to adopt policy measures essential for supporting the development of innovative cancer treatments, meeting the unmet needs of patients with cancer, and supporting the work of medical oncologists in Europe and beyond.

Metastatic Breast Cancer: ESMO Clinical Practice Guideline

noreply@esmo.org — Fri, 29 May 2026 11:05:00 +00:00

Ground-breaking advances in systemic treatments have improved prognosis, particularly in certain subtypes. The updated ESMO CPG covers diagnosis, staging, local and systemic treatment and follow-up.

EMA Recommends Extending Indications for Decitabine / Cedazuridine

noreply@esmo.org — Fri, 29 May 2026 07:05:00 +00:00

New indication concerns a combination with venetoclax for the treatment of adult patients with newly diagnosed AML

ESMO Welcomes the European Commission’s (EC) New Global Health Resilience Initiative (GHRI) and Urges Countries to Ensure Continuity of Cancer Care During Crises

noreply@esmo.org — Fri, 29 May 2026 07:05:00 +00:00

Earlier in 2026, ESMO advised the EC to ensure that cancer prevention and control were integrated into the GHRI, warning that the COVID-19 pandemic had demonstrated how disruptions to oncology services could increase patient mortality and widen inequalities.